From Complexity to Clarity: Redefining Regulatory & Artwork Operations Through AI
Healthcare is facing a paradox. On one hand, AI is driving a technological revolution, outperforming emergency room physicians in clinical reasoning and diagnosing rare conditions that stumped human experts. On the other hand, the pharmaceutical back-end, specifically regulatory affairs, labelling, and artwork operations, remains bound by rigid, slow, and human-heavy verification processes. The question is no longer whether AI has a place in life sciences. The question is: Can your AI stand up to an EMA or MHRA inspection?
At Vakils, we believe the future belongs to those who bridge this gap, moving from the chaos of unchecked innovation to the clarity of compliant, defensible AI.
The Macro View: Why Healthcare Needs AI
The current human-led healthcare system is pushed to its absolute limits. AI introduces consistency and scale. A landmark Harvard study published in Science showcased OpenAI’s o1 model outperforming attending emergency room physicians across 76 real patient cases. The AI achieved a 67.1% correct diagnosis rate at triage (compared to ~50–55% from physicians) and identified a rare, life-threatening infection 12 to 24 hours earlier than the clinical team. But while the clinical world is embracing AI for decision support, the regulatory landscape requires a fundamentally different approach.
The Regulatory Reality: AI is Easy, Defensibility is Hard
In highly scrutinised markets, the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) maintain a crystal-clear stance: Innovation does not override accountability. The FDA tells you exactly what “good” looks like; the EMA and MHRA expect you to prove it under intense scrutiny, with no pre-written script.
Regulated content is a different beast entirely. Pharma labelling, patient information leaflets (PILs), and packaging artwork are GxP-governed and legally attributable to the Marketing Authorisation Holder (MAH). Under inspection, every label must be:
- Controlled: Zero room for algorithmic “hallucinations” or creative phrasing.
- Traceable: A clear audit trail of who, what, why, and when.
- Justifiable: A documented rationale that human auditors can verify.
Because of this compliance gap, the EMA and MHRA explicitly dictate that AI must not author regulated content or replace human accountable decision-making
Where AI Wins Today: Defensible Use Cases
The most successful applications of AI in regulatory operations do not replace humans; they augment them. By aligning AI with data integrity principles, EU GMP Annex 11 (Computerised Systems), Annex 15 (Validation), and GAMP 5 expectations, companies can safely deploy AI for:
- Cross-Label Consistency Checks: Scanning global artwork to catch discrepancies in side effects, dosages, or warnings across markets.
- Change Impact Analysis: Automatically identifying every document, leaflet, and submission impacted by a single regulatory variation.
- Inspection Evidence Preparation: Compiling the regulatory history and lineage of a label so it is instantly ready for an auditor’s review.
Vakils Role: Wrapping AI Inside Compliance
Most AI tools on the market are engineered for absolute speed and continuous learning. But pharma artwork and labelling require fixed, repeatable outputs. Vakils doesn’t just introduce AI into pharma, we wrap AI inside EMA/MHRA-compliant operating models.
We integrate intelligent automation directly into your Artwork Management System (AMS) platforms, workflows, and validation frameworks. We ensure that every automation step surfaces risk, highlights inconsistencies, and improves inspection readiness without ever breaking the chain of human accountability.
In this new era, governance will define the winners, and trust will separate the leaders from the followers. Vakils helps pharmaceutical leaders develop artwork labelling ecosystems that the EMA/MHRA can inspect, QA can validate, and leadership can confidently defend.
Email us at info@vakilspremedia.com for more details on our AI-backed artwork labelling service offerings.
